These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1751 related articles for article (PubMed ID: 32517735)

  • 1. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple negative breast cancer: special histological types and emerging therapeutic methods.
    Cao L; Niu Y
    Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative breast cancer: is there a treatment on the horizon?
    Yao H; He G; Yan S; Chen C; Song L; Rosol TJ; Deng X
    Oncotarget; 2017 Jan; 8(1):1913-1924. PubMed ID: 27765921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecularly targeted therapies for metastatic triple-negative breast cancer.
    Bayraktar S; Glück S
    Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
    Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
    BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of triple-negative breast cancer.
    Kumar P; Aggarwal R
    Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
    Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
    Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
    Damaskos C; Garmpi A; Nikolettos K; Vavourakis M; Diamantis E; Patsouras A; Farmaki P; Nonni A; Dimitroulis D; Mantas D; Antoniou EA; Nikolettos N; Kontzoglou K; Garmpis N
    Anticancer Res; 2019 Oct; 39(10):5285-5296. PubMed ID: 31570423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
    Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
    Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Progress in Triple Negative Breast Cancer Research.
    Mouh FZ; Mzibri ME; Slaoui M; Amrani M
    Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
    Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
    Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology of triple negative breast cancer.
    Borri F; Granaglia A
    Semin Cancer Biol; 2021 Jul; 72():136-145. PubMed ID: 32544511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer.
    Zhao Z; Li L; Du P; Ma L; Zhang W; Zheng L; Lan B; Zhang B; Ma F; Xu B; Zhan Q; Song Y
    Theranostics; 2019; 9(5):1401-1416. PubMed ID: 30867840
    [No Abstract]   [Full Text] [Related]  

  • 19. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
    Nouri Emamzadeh F; Word B; Cotton E; Hawkins A; Littlejohn K; Moore R; Miranda-Carbon G; Orish CN; Lyn-Cook B
    Anticancer Res; 2020 Jul; 40(7):3669-3683. PubMed ID: 32620606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.